

Core Team Meeting Minutes
July 17, 1997

Attendees: J. Walling, M. Arnett, G. Thompson, M. Miller, K. Hartsock, D. Gardner, D. Balogh
D. Thornton, S. Hamburger, C. Niyikiza, B. Tauke, J. Woodworth.
Via teleconference: E. Ruighaver, F. Martelet.

Please submit corrections to Jim Wilkins by July 28, 1997

1. D. Thornton and C. Niyikiza presented some very **encouraging news**: There is a possible correlation between increased Homocystine levels and Toxicity, and the hypothesis that Vitamin Supplementation prior to and during treatment could eliviate some toxicity . This potential theory, if clinically proven could possibly be patented and utilized with other drugs such as GARFT.
More Information to follow as available.
2. D. Gardner gave a update on Study enrollment:
JMBB - 29 patients enrolled with 5 Stable Disease reports to date.
JMBM - 20 Patients enrolled, we are expecting several Scans coming in the next few weeks.
JMBN- Enrollment up to 10 patients to include some Chemo-Nieve Patients.
There is to date only 4 non-evaluable patients across the board on above listed studies.
3. ECCO:
D. Gardner stressed that they have identified a **lodging problem** and at this point the **closest available hotel** to the meeting site is **40 miles away**.
Recommendation: Decisions on attendance need to be made **ASAP**, and arrangements to be coordinated through Diana Kelley.
4. Discussion : Regarding the process for presentation of MTA at ECCO, the decision is to still be made on weather a representative from ILEX or from Lilly will conduct the PK analysis. Also the determination is to still be made on weather we will focus on MTA as a hole, or on just the Renal Impaired data.
J. Woodward stated that the Internal Lilly PK department has increased staff, and he believes that the can handle the presentation, he is to confirm and get back to the team.
5. J. Walling to drop a letter to Joe Bertino this afternoon to confirm his involvement in the 1Hr presentation. They are to look at the Pre-Clinical data, to determine what additional data is needed to position LY231514 as a multi-targeted antifolate.
6. Agenda topics: Head & Neck Prognostic Markers, and Reference Database were tabled until the next meeting due to time constraints.

Meeting was adjourned.



CONFIDENTIAL

TRIAL EXHIBIT

TX 64

AV00365851